Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Discollection of information unless it contains a valid OMB control number.

Cubetitut	te for form 1449/PTO			Complete if Known		
, Ohnsuidi	le loi loilli 1443/F 10			Application Number	10/532,390	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	Oct/24/2003	
				First Named Inventor	Haj-Yehia	
	4 1	4		Art Unit	N/A	
(Use as many sheets as necessary)				Examiner Name	N/A	
Sheet	l	of	1	Attorney Docket Number	0-06-225	7

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	:	Remington: The Science and practice of Pharmacy 20th Ed. (2000), Lippincott Williams and Wilkins, BOOK	
		SP Sanderset et al. "Spontaneous oxygen radical productionin allergic subjects". American Journal of Respiratory and Critical Care Medicine. 151: 1725-33 (1995)	
12.1517-		Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, Ed. Hardman, J. G. and Limbird, L. E., 10th Ed., 2001, McGraw-Hill, Medical Publishing Division; BOOK	•
		Eileen G. Holland, A. Thomas Taylor (Dec. 1991) "Practical management of stress-related gastric ulcers" Journal of Family Practice. 31:512-519	
		March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th Edition (2000) M.B. Smith & J. March, John Wiley & Sons, New York. BOOK	
		Organic Chemistry 6th Ed. (1992) R. Morrison & R. Boyd, Benjamin Cummings, San Francisco; BOOK	
		S.L. Swartz, R.G. Dluhy. "Corticosteroids: Clinical pharmacology and therapeutic use" (1978) Drugs 16(3):238-255	

Examiner	Date	· •
Signature	Considered	i

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND PRES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.